Methods are disclosed for delivering a composition comprising an adeno-associated
virus (AAV) to one or more
kidney cell types in a subject with or without
immunity against AAV, including locally delivering to the
kidney of the subject an adeno-associated
virus (AAV) comprising a
genome and an AAV
capsid protein via renal pelvic injection, wherein the renal pelvic injection comprises direct renal pelvic injection or retrograde transureteral renal pelvic injection. Methods are also disclosed for treating a
kidney disorder in a subject with or without
immunity against AAV, comprising locally delivering to the kidney of the subject via renal pelvic injection, including direct renal pelvic injection and retrograde transureteral renal pelvic injection, an adeno-associated
virus (AAV) comprising a
genome and an AAV
capsid protein, wherein the
genome encodes a therapeutic agent that treats the
kidney disorder in the subject. The AAV can be AAVKP1, AAVKP2, AAVKP3, AAVDJ, AAV2G9, AAV2.7m8, AAV3, AAVLK03, or AAVShH10.